Skip to main content
. 2018 Oct 10;19(6):166–176. doi: 10.1002/acm2.12474

Table 1.

Target coverage evaluated by cumulative treatment dose

Patient # Txplanplan×100% D99 (cGy) Prescription (cGy × fractions) Tumor position Excursion (mm) GTV (CC)
D99 (%) D95 (%) D90 (%)
Lung 1 96.5 97.4 98.1 6858.1 1200 × 5 RLL 6.0 2.34
Lung 2 94.7 96.4 97.4 5394.0 1200 × 4 LLL 6.1 1.57
Lung 3 93.6 93.3 93.5 5306.5 1200 × 4 RLL 5.7 8.94
Lung 4 100.1 102.1 102.6 5620.7 1200 × 4 RLL 7.1 6.18
Lung 5 94.4 96.7 97.5 5307.7 1200 × 4 RLL 13.2 3.69
Lung 6 83.7 84.6 86.3 5223.75 1000 × 5 RLL 7.8 0.85
Average 93.8 95.1 95.9 7.62 3.93
H&N 1 97.0 98.7 99.8 3779.7 180 × 22
H&N 2 100.0 100.1 100.2 7150.9 200 × 35
Breast 93.3 98.5 99.8 4203.1 200 × 25
Prostate 101.30 102.20 103.40 7968.0 180 × 44